logo.jpg
Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
May 06, 2021 16:05 ET | Lexicon Pharmaceuticals, Inc.
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the...
logo.jpg
Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021
April 29, 2021 16:14 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the...
logo.jpg
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 16:35 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s executive vice president, corporate and...
logo.jpg
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update
March 10, 2021 16:10 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and...
logo.jpg
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
March 04, 2021 16:05 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10,...
logo.jpg
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
January 14, 2021 08:00 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback...
logo.jpg
Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 08:00 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present...
logo.jpg
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
December 31, 2020 08:00 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized,...
logo.jpg
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
December 16, 2020 16:05 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of...
logo.jpg
Lexicon Announces Offering of Common Stock
December 11, 2020 08:02 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain...